Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
H2AZ2 divergent transcript (H2AZ2-DT), also known as AC004854.4 or LINC01952, is a long non-coding RNA (lncRNA)[3]. LncRNAs are a class of RNA molecules longer than 200 nucleotides that do not code for protein but may regulate gene expression at various levels, including chromatin modification, transcription, and post-transcriptional processing. The H2AZ2-DT gene is affiliated with the lncRNA class and has been associated in database annotations with diseases such as retinitis pigmentosa[3]. However, there is limited functional characterization of this specific transcript, and its precise biological role, molecular interactions, and suitability as a therapeutic target remain unestablished. There is no evidence in the current literature that H2AZ2-DT encodes a protein or functions as a classical therapeutic target, such as a receptor, enzyme, transporter, or ion channel[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on H2AZ2 divergent transcript (H2AZ2-DT).